Literature DB >> 33895836

Peritraumatic Plasma Omega-3 Fatty Acid Concentration Predicts Chronic Pain Severity Following Thermal Burn Injury.

Matthew C Mauck1,2, Chloe E Barton1,2, Andrew S Tungate1,2, Jeffrey W Shupp3, Rachel Karlnoski4, David J Smith4, Felicia N Williams5, Samuel W Jones5, Christopher Sefton1,2, Kyle McGrath1,2, Bruce A Cairns5, Samuel A McLean1,2,6.   

Abstract

Chronic pain is a significant comorbidity of burn injury affecting up to 60% of survivors. Currently, no treatments are available to prevent chronic pain after burn injury. Accumulating evidence suggests that omega-3 fatty acids (O3FAs) improve symptoms across a range of painful conditions. In this study, we evaluated whether low peritraumatic levels of O3FA predict greater pain severity during the year after burn injury. Burn survivors undergoing skin autograft were recruited from three participating burn centers. Plasma O3FA (n = 77) levels were assessed in the early aftermath of burn injury using liquid chromatography/mass spectrometry, and pain severity was assessed via the 0 to 10 numeric rating scale for 1 year following burn injury. Repeated-measures linear regression analyses were used to evaluate the association between peritraumatic O3FA concentrations and pain severity during the year following burn injury. Peritraumatic O3FA concentration and chronic pain severity were inversely related; lower levels of peritraumatic O3FAs predicted worse pain outcomes (β = -0.002, P = .020). Future studies are needed to evaluate biological mechanisms mediating this association and to assess the ability of O3FAs to prevent chronic pain following burn injury.
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Burn Association. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 33895836      PMCID: PMC8737082          DOI: 10.1093/jbcr/irab071

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  54 in total

Review 1.  Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.

Authors:  Harold Bays
Journal:  Am J Cardiol       Date:  2006-05-30       Impact factor: 2.778

2.  Safety and efficacy of Omacor in severe hypertriglyceridemia.

Authors:  W S Harris; H N Ginsberg; N Arunakul; N S Shachter; S L Windsor; M Adams; L Berglund; K Osmundsen
Journal:  J Cardiovasc Risk       Date:  1997 Oct-Dec

3.  Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial.

Authors:  Christopher E Ramsden; Keturah R Faurot; Daisy Zamora; Chirayath M Suchindran; Beth A MacIntosh; Susan Gaylord; Amit Ringel; Joseph R Hibbeln; Ariel E Feldstein; Trevor A Mori; Anne Barden; Chanee Lynch; Rebecca Coble; Emilie Mas; Olafur Palsson; David A Barrow; Douglas J Mann
Journal:  Pain       Date:  2013-07-22       Impact factor: 6.961

Review 4.  Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review.

Authors:  Marianne Jensen Hjermstad; Peter M Fayers; Dagny F Haugen; Augusto Caraceni; Geoffrey W Hanks; Jon H Loge; Robin Fainsinger; Nina Aass; Stein Kaasa
Journal:  J Pain Symptom Manage       Date:  2011-06       Impact factor: 3.612

5.  Estimation of minimum clinically important difference for pain in fibromyalgia.

Authors:  Philip J Mease; Michael Spaeth; Daniel J Clauw; Lesley M Arnold; Laurence A Bradley; I Jon Russell; Daniel K Kajdasz; Daniel J Walker; Amy S Chappell
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-06       Impact factor: 4.794

Review 6.  Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression.

Authors:  Brian Hallahan; Timothy Ryan; Joseph R Hibbeln; Ivan T Murray; Shauna Glynn; Christopher E Ramsden; John Paul SanGiovanni; John M Davis
Journal:  Br J Psychiatry       Date:  2016-04-21       Impact factor: 10.671

7.  Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids.

Authors:  Joo Y Lee; Anthony Plakidas; Won H Lee; Anne Heikkinen; Prithiva Chanmugam; George Bray; Daniel H Hwang
Journal:  J Lipid Res       Date:  2002-12-01       Impact factor: 5.922

8.  The Effect of Omega-3 Fatty Acids in Patients With Active Rheumatoid Arthritis Receiving DMARDs Therapy: Double-Blind Randomized Controlled Trial.

Authors:  Elham Rajaei; Karim Mowla; Ali Ghorbani; Sara Bahadoram; Mohammad Bahadoram; Mehrdad Dargahi-Malamir
Journal:  Glob J Health Sci       Date:  2015-11-03

9.  Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.

Authors:  R J T Mocking; I Harmsen; J Assies; M W J Koeter; H G Ruhé; A H Schene
Journal:  Transl Psychiatry       Date:  2016-03-15       Impact factor: 6.222

10.  Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on ω-3 supplementation.

Authors:  Sam Famenini; Elizabeth A Rigali; Henry M Olivera-Perez; Johnny Dang; Michael To Chang; Ramesh Halder; Rammohan V Rao; Matteo Pellegrini; Verna Porter; Dale Bredesen; Milan Fiala
Journal:  FASEB J       Date:  2016-09-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.